Background-9p21.3 is among the most strongly replicated regions for cardiovascular disease. There are few reports of sequencing the associated 9p21.3 interval. We set out to sequence the 9p21.3 region followed by a comprehensive study of genetic associations with clinical and subclinical cardiovascular disease and its risk factors, as well as with copy number variation and gene expression, in the Framingham Heart Study (FHS). Methods and Results-We sequenced 281 individuals (94 with myocardial infarction, 94 with high coronary artery calcium levels, and 93 control subjects free of elevated coronary artery calcium or myocardial infarction), followed by genotyping and association in >7000 additional FHS individuals. We assessed genetic associations with clinical and subclinical cardiovascular disease, risk factor phenotypes, and gene expression levels of the protein-coding genes CDKN2A and CDKN2B and the noncoding gene ANRIL in freshly harvested leukocytes and platelets. Within this large sample, we found strong associations of 9p21.3 variants with increased risk for myocardial infarction, higher coronary artery calcium levels, and larger abdominal aorta diameters and no evidence for association with traditional cardiovascular disease risk factors. No common protein-coding variation, variants in splice donor or acceptor sites, or copy number variation events were observed. By contrast, strong associations were observed between genetic variants and gene expression, particularly for a short isoform of ANRIL and for CDKN2B. Conclusions-Our thorough genomic characterization of 9p21.3 suggests common variants likely account for observed disease associations and provides further support for the hypothesis that complex regulatory variation affecting ANRIL and CDKN2B gene expression may contribute to increased risk for clinically apparent and subclinical coronary artery disease and aortic disease. (Circulation. 2013;127:799-810.)
T he human chromosome 9p21.3 region, which contains the protein-coding genes CDKN2A and CDKN2B and the noncoding gene ANRIL, is one of the strongest and most consistently replicated genetic regions to emerge from genome-wide association studies (GWAS). Single-nucleotide polymorphisms (SNPs) in 9p21.3 are associated most strongly with myocardial infarction (MI) and coronary artery disease 1 but are also associated with abdominal 2, 3 and intracranial 3 aneurysm, type 2 diabetes mellitus (eg, Grarup et al 4 ), cancers, 5, 6 peripheral artery disease, 3, 7 and coronary artery calcium (CAC), a measure of subclinical coronary artery atherosclerosis, 8, 9 which suggests phenotypic pleiotropy of associations in the region. More modest associations have also been observed with incident heart failure, 10 sudden cardiac death, 11 and coronary stenosis, 12 and weakly and somewhat inconsistently with stroke. 13 Thus far, the associations with cancer risk and type 2 diabetes mellitus appear distinct, by physical location and correlation among the most strongly associated SNP, from the peak cardiovascular disease (CVD) associations that are located primarily in the 3′ region of ANRIL.
Clinical Perspective on p 810
Various groups have reported that SNPs associated with cardiovascular outcomes are associated with the gene expression of ANRIL, CDKN2A, and CDKN2B, which suggests that differences in regulatory elements may explain at least in part the functional contribution of risk alleles to disease phenotypes. 3, [14] [15] [16] [17] [18] [19] [20] [21] The majority of the studies on 9p21.3 to date have focused on either single SNPs or directly genotyped or imputed SNPs in GWAS based on commercial genotyping arrays. Few groups have yet reported large-scale resequencing of the 9p21.3 region 18, 22 or on the presence or absence of copy number variations (CNVs) in the region, 1 and to date, reports have included only relatively small sample sizes. We set out to sequence the 9p21.3 region in 3 groups of participants selected by presence of MI or subclinical coronary artery disease (total n=281) in the Framingham Heart Study (FHS) to discover new variation and follow up novel and known variants in a larger set of FHS participants (n>7000) to test associations with clinical and subclinical CVD, as well as CVD risk factors. We additionally sought to test for association with expression (mRNA) of genes in the region in several thousand individuals in leukocytes and platelets, to construct a denser linkage disequilibrium (LD) map in the region than available in the HapMap, and to determine whether common CNVs exist in the 9p21.3 region and whether it is associated with disease or its risk factors.
Methods
The FHS is a community-based, prospective, longitudinal study of 3 generations of participants. The original cohort enrolled 5209 participants starting in 1948, 23 the Offspring (Second Generation) cohort enrolled 5124 children and spouses of children of the original cohort starting in 1971, 24 and the Third Generation enrolled 4095 children of the Offspring cohort in [2002] [2003] [2004] [2005] . 25 Subjects from families were recruited for computed tomography (CT) scans that included 1390 offspring (Second Generation) cohort participants at examination 7 and 2093 third-generation participants at examination 1. Participants for sequencing and association analysis (n=281) in the discovery sequencing stage were drawn from the offspring cohort, as described below. Participants for genotyping and association analysis (up to n=7290) in the follow-up genotyping stage were drawn from the offspring and third-generation cohorts, as described below. The overall study design, flow, and key Table references 
Subclinical and Clinical CVD and Risk Factor Phenotypes Studied in FHS Participants
CAC, abdominal aortic calcium (AAC), and aortic diameters were measured by an 8-slice cardiac multidetector scanner (Lightspeed Ultra, GE, Milwaukee, WI) as described previously. 26 CAC scores were calculated by a modified Agatston score based on the average of 2 sequential scans. There were 3238 FHS participants with both CAC and follow-up genotyping available for analysis. The CAC dichotomous categories were defined as low (mean CAC value <100) and high (mean CAC ≥100). AAC continuous measures were averaged from ≥2 measurements, with 3316 participants also having genotypes available. CT measurements of anteroposterior arterial diameters were calculated. Among individuals with genotypes, diameter measurements were available in participants, ranging from 3287-3300, at 4 anatomic sites: The ascending and descending thoracic aorta at the level of the right pulmonary artery, and the abdominal aorta 5 cm above and at the aortoiliac bifurcation. Individuals with known CVD or abdominal or thoracic surgeries were excluded.
Recognized MI and other coronary artery disease were defined as described previously, adjudicated by a panel of physicians, and included ECG, cardiac biomarker, case history, and autopsy evidence. 27 Hard coronary heart disease was defined as death caused by CVD or a recognized MI. Prevalent events were identified across all available examinations, whereas incident events were identified as those that took place after the DNA collection for each individual. Age of onset for MI was defined with the date of the first documented event relative to birth date. Among those in the follow-up genotyping stage, 113 prevalent MI cases and 72 incident MI cases were available for analysis.
CVD risk factors were collected as described previously. 27 The risk factors were measured at the same examination for each cohort as the CAC and AAC measurements and included total cholesterol, high-density lipoprotein cholesterol, log (triglyceride levels), body mass index, systolic blood pressure, hypertension (defined as systolic blood pressure ≥140 or diastolic blood pressure ≥90 mm Hg or treatment with antihypertensive medication), prevalence of type 2 diabetes mellitus (defined as a fasting plasma glucose level ≥126 mg/dL or use of antidiabetic treatment), and cigarette smoking (current smoker, regularly smoked ≥1 cigarette/d within the last 12 months). Each of these risk factors was included in the multivariable-adjusted models along with the reported use of lipid-lowering medication.
Selection of Unrelated Individuals in 3 Groups for the Discovery Resequencing Stage
Participants from the FHS offspring cohort were selected in 3 groups based on presence or absence of prior clinically apparent MI or high CAC for 9p21.3 resequencing: Group I, individuals with early-onset (men <55 years old, women <65 years old) MI (n=94); group II, individuals with no recognized MI but high age-and sex-adjusted CAC, 28 defined as being in >90th percentile (n=94; mean±SD: males 1775±1466, females 544±631); and group III, individuals with no recognized MI and with low age-adjusted CAC, defined as a value <25th percentile (n=93; mean±SD: males 8±16, females, 0±0). Characteristics of the 3 groups are provided in online-only Data Supplement Table I . To account for the family structure within FHS, we preferentially selected 1 participant per pedigree, emphasizing individuals with earliest onset of MI, with highest CAC value, or with lowest sex-specific CAC within pedigrees with no evidence for MI or high CAC. Participants <58 years old at the time of CT scan were excluded from group III. A set of males (n=52) met criteria for group III and were selected to provide a comparable sex distribution with group II. Of females meeting the criteria, 44 were randomly selected to yield a total of 94 participants in group III. Sequencing results were only available for 93 individuals in group III because 1 sample had average call rates <80% across the 9p21.3 region.
Resequencing of 9p21.3 in 281 FHS Participants
Genomic DNA was whole genome amplified, and ≈15 µg was transferred to each of 2 resequencing centers (the J. Craig Venter Institute and the University of Washington, Department of Genome Sciences sequencing center). The full targeted region for Sanger-based resequencing was 250 000 bases on chromosome 9 between 21 940 000 and 22 190 
Association Analysis of Variants Identified by Sequencing
Biallelic SNP variants with minor allele frequency (MAF) ≥2.0% were tested for association across groups under an additive model with adjusted for age and sex. For each variant, 2 group comparisons were made: (1) for MI, group I (MI) versus group III (no MI, low CAC), and (2) for CAC, group II (no MI, high CAC) versus group III (no MI, low CAC). Furthermore, each SNP was tested for differences in group allele counts with both χ 2 tests and Fisher exact tests to try to improve performance for rarer variants. Variants with ≥1 group comparison having P<0.05 were selected for follow-up genotyping in a larger sample of FHS participants.
Burden Testing of 9p21 Variants in ARIC and CHS Cohorts
Variants in the same 9p21 region assessed in the FHS were extracted from whole genome sequence data in the Atherosclerosis Risk in Communities study (ARIC) and Cardiovascular Health Study (CHS) cohorts (n=187 MI/coronary heart disease cases from baseline, n=454 controls). Sequence kernel association tests 29 and T1 burden tests, 30 with adjustment for age, sex, and study site, were applied to the whole region, as well the 4 individual gene regions (see online-only Data Supplement for further details).
Follow-Up Genotyping in 7290 FHS Participants of SNPs Identified by Sequencing
A total of 172 SNPs in the 9p21.3 region were selected for further genotyping as follows: P<0.05 for both MI and high CAC (n=27), P<0.05 for MI alone (n=106), P<0.05 for high CAC alone (n=22), SNPs in the region of densest prior reported associations that had poor call rates by sequencing that included rs1333049 (n=8), SNPs with prior haplotype associations that were not significant in the discovery sequencing stage analysis (n=2), and SNPs with large differential genotype counts between MI or high CAC groups and control groups that did not reach significance in the discovery sequencing stage (n=7). The SNPs were submitted for assay design QC (Illumina, Inc, San Diego, CA), with 140 SNPs receiving good quality metrics and therefore selected for final genotyping. FHS participants with available genomic DNA with cell line backups and with prior genotyping in the SNP Health Association Resource (SHARe) project with a genome-wide call rate >97% were selected for genotyping (n=7379). Characteristics of the follow-up stage participants are provided in online-only Data Supplement Table  II . Genotyping of 140 SNPs was conducted by Illumina Golden Gate assay. After DNA sample genotyping failures were excluded (n=89), SNP results were available for analysis in 7290 FHS participants, including 260 of 281 participants included in the discovery sequencing stage. Twenty of those from discovery sequencing were not genotyped because they did not have plated genomic DNA with adequate cell line backups. Follow-up genotyping failed in 1 discovery sample. Genotyping failed in 14 of 140 attempted SNPs, which left 126 SNPs available for analysis (average call rate for successful SNPs, 99.85%).
Figure. Top, Regional plots of genotype-phenotype associations in the follow-up stage. Peak single-nucleotide polymorphisms are labeled (top to bottom) for associations with prevalent myocardial infarction (MI; rs4977574), coronary artery calcium (rs1333045), abdominal aortic aneurysm (rs1333046), type 2 diabetes mellitus (rs10811661), and ANRIL short isoform (rs944799) and CDKN2B (rs598664) expression in leukocytes. Bottom, Detected copy number (CN) events are listed in number of minor alleles (gain or loss). The relative positions and transcript directions for CDKN2A, CDKN2B, and ANRIL are indicated. A pairwise plot of linkage disequilibrium (LD) is shown based on randomly selected unrelated individuals (n=1170) in the Framingham Heart Study. AAO indicates ascending thoracic aorta at the level of right pulmonary artery; ABAO, abdominal aorta at the aortic-common iliac bifurcation; ABAO-5, abdominal aorta 5 cm above the aortic-common iliac bifurcation; BMI, body mass index; CNVs, copy number variations; CVD, cardiovascular disease; DAO, descending thoracic aorta at the level of right pulmonary artery; HDL, high-density lipoprotein; and SBP, systolic blood pressure. 
Association Analysis for 126 SNPs With Disease and Risk Factors in 7290 FHS Participants
Regression models were used to examine associations with clinical CVD events, subclinical CVD ascertained by CT (CAC, AAC, aortic diameters), and traditional CVD risk factors. Association analyses for CAC and AAC were conducted after adjustment for age at CT scan and sex, as well as separately with multivariable risk factors. Associations with CT aortic diameters (ascending thoracic aorta, descending thoracic aorta, and abdominal aorta 5 cm above and at the aortic-common iliac bifurcation) were conducted after adjustment for age, height, and sex. Associations with traditional CVD risk factors were tested in age-and sex-adjusted models.
Primary follow-up stage analyses were conducted on all participants successfully genotyped to maximize statistical power. This included 260 of 281 participants sequenced in the discovery sequencing stage. Secondary analyses were also conducted with the 7030 participants not sequenced in the discovery stage and yielded similar results. Analysis of continuous traits used a linear mixed-effects model with a random effects component to account for relatedness in FHS, as described previously. 31 Additive, recessive, and dominant models were analyzed for all continuous traits. Dichotomous traits were analyzed with general estimating equations as described previously. 31 Conditional age-and sex-adjusted association analyses were conducted for continuous and dichotomous CAC by including a covariate for SNP genotype in the model for each of the top 2 SNPs in turn (rs1333049, rs1333045) to determine which associations remained after accounting for these variants.
LD and Effective Number of Tests
Because our study included novel variants from sequencing and a larger sample number than the HapMap CEU reference sample commonly used in GWAS imputation, we created an LD map based on 1170 unrelated individuals in the FHS offspring cohort. Genotype results were combined from the follow-up genotyping stage for all nonmonomorphic SNPs (n=125) and from prior GWAS studies in the FHS (n=23 additional SNPs). One participant was randomly selected from each family, and genotypes for 1170 unrelated individuals were loaded into Haploview (v4.2) to calculate haplotypes and pairwise LD (Figure) . There were 67 of 126 tested SNPs that were perfectly correlated with ≥1 other SNP (the 67 SNPs were in 22 distinct intracorrelated groups Gene Expression Analysis of CDKN2A, CDKN2B and ANRIL Citrated venous blood was collected from Offspring Examination 8 participants as described previously. 32 Briefly, either platelet-rich plasma was isolated by centrifugation and filtered to remove white blood cell contaminants, or separately, peripheral mononuclear cells were isolated from whole blood buffy coats by centrifugation in CPT Ficoll separation tubes (Becton Dickinson, Franklin Lakes, NJ). Pellets were lysed with total RNA lysis solution (Qiagen, Germantown, MD) and frozen at −80°C. Total RNA was isolated with RNeasy Mini kits and purified with a Qiacube instrument (Qiagen). RNA quantity and quality were evaluated by NanoDrop Spectrophotometer (NanoDrop, Wilmington, DE). Complementary DNA (cDNA) was prepared with high-capacity cDNA reverse-transcription kits (Applied Biosystems), and preamplification was conducted with a TaqMan PreAmp Master Mix (Applied Biosystems). Quantitative real-time polymerase chain reaction was run with TaqMan assays in DynamicArray 48.48 chips on a BioMark RTPCR system (Fluidigm, San Francisco, CA). TaqMan probe sequences for CDKN2A, CDKN2B, and ANRIL long and short isoforms are given in online-only Data Supplement Table IV. Of the Offspring cohort participants with gene expression measurements, up to 1499 also had follow-up stage genotyping, CAC measurement (n up to 618), or AAC measurement (n up to 653). Gene expression levels were normalized to the mean cycle threshold of 3 control genes within samples (β-actin, ACTB; β-2-microglobulin, B2M; and GAPDH) by the 2 −∆∆ CT method. Samples with cycle threshold values ≥30 for target genes or for all control genes were excluded from analysis. Because of the non-normal distribution of result after normalization, relative expression levels were log-transformed before analysis. Association of SNPs with gene expression was evaluated under additive and recessive models and adjusted for either age or age and sex. Association of expression levels with CAC or AAC was evaluated with linear mixed effects with adjustment for age and, alternatively, age and sex. Only 516 variants from the discovery sequencing stage with minor allele counts ≥5 are included. Genes considered include C9orf53 and multiple isoforms of CDKN2A, CDKN2B, and ANRIL (also known as CDKN2BAS).
SNPs indicates single-nucleotide polymorphisms; and UTR, untranslated region. 
CNV Calling and Analysis
Genotype intensities from the Affymetrix 500K (StyI and NspI arrays) for ≈8700 individual FHS samples with genome-wide call rates >97% were subjected to quantile normalization to the median intensity of a reference group of samples (Golden Helix SNP & Variation Suite, Bozeman, MT). A logR ratio for individuals at each marker was calculated and corrected with principal components analysis for genotyping batch effects (Golden Helix SNP & Variation Suite). Extreme outliers of logR ratios were excluded, and CNVs were called as neutral (no gain or loss), a gain (≥1 copy), or a loss (≥1 copy). In total, 425 SNPs were evaluated for potential CNV on chromosome 9 in a region that stretched from rs7025851 (at position 20 951 906) to rs1416509 (at position 23 055 716). This region surrounds our targeted sequencing and association region by ≈1 Mb on either side.
Results

Discovery Sequencing Stage Variant Rates and Results of Discovery Association Analyses
We found 1363 biallelic SNPs (excluding indels) and 55 complex variants (including single-nucleotide and multinucleotide insertions and deletions) that were present in 1 or more sample (Table 1) . Of all the variants, 651 (636 SNPs, 15 complex variants) were singletons. After categorizing them against known variants in dbSNP Build 128, we found that 1011 (71.3%) of 1418 variants were novel. The novel variants clustered toward lower MAFs (Table 1) , and overall, there appeared to be an excess of variants of low MAF in those in group I (early-onset MI; n=345 alleles counted with MAF<0.5%) or group II (high levels of CAC; n=312 allele counts) compared with group III (no prior MI and low CAC; n=286 allele counts), as shown in online-only Data Supplement Table V . Additional MI/coronary heart disease cases and controls were sequenced for the same 9p21 region in the ARIC and CHS studies. Burden testing in ARIC plus CHS for the whole region and for 4 gene subregions indicated the most significant result for sequence kernel association tests across the whole 9p21 region (P=0.052; online-only Data Supplement Table VI) .
As shown in Table 2 , most of the 516 variants in FHS with minor allele counts ≥5 were within a transcribed portion of the targeted region (322/516, 60.5%) and located within introns (300/516, 58.1%). Eleven of the 22 exonic variants were located within the noncoding RNA ANRIL, 8 were located in 3′ untranslated regions, 2 were within 5′untranslated regions, and 1 was a known nonsynonymous variant (rs3731249, Ala148Thr in CDKN2B, MAF 2.1%). One novel variant was found to encode an A>C change within an AG splice acceptor sequence in intron 6 of ANRIL (hg18 position 22 046 249, MAF 0.9%). Two of the 3′ untranslated region variants (rs3217992 in CDKN2A with MAF 42.9%, rs3088440 in CDKN2B with MAF 9.4%) are in predicted microRNA binding sites (http:// www.patrocles.org/). None of these potentially functional variants were associated with either MI or CAC in the discovery sequencing stage association results (all P>0.05), and none were selected for follow-up genotyping.
Follow-up Genotyping Stage Associations With Clinical CVD, Subclinical CVD, and Risk Factors
On the basis of the discovery stage results (top results in Table 3 ; full results in online-only Data Supplement Table III) , 140 SNPs were selected for further genotyping; of these, 126 SNPs were genotyped successfully (quality control information in online-only Data Supplement Table  III) . We observed strong associations in the follow-up genotyping stage with CAC levels as a continuous phenotype (P<5×10 −9 ; Table 4 ). We examined other associations for the strongest CAC-associated SNP (rs1333045) in further detail, as well as for the 9p21.3 SNP that has been most studied in the literature (rs1333049; r 2 =0.84 with rs1333045 in FHS). Both SNPs were also associated with increasing abdominal aortic diameter and prevalent MI but were not strongly associated with any CVD risk factors (Table 4 ). In single SNP analyses or conditional analyses (adjusted for either SNP), rs1333045 showed stronger association with CAC. The magnitude, direction, and statistical significance of these findings were similar in multivariable analyses (adjusting for age, sex, and all traditional CVD risk factors) of the association of both SNPs with CAC phenotypes (data not shown). The strongest individual SNP associations from the followup genotyping stage for all measures are shown in Table 5 . Only associations for CAC, abdominal aortic diameter, and prevalent MI survived a multiple-test correction (P<6.2×10 −4 ). Notably, the peak SNP for prevalent MI (rs4977574) was the same SNP with previous, strong associations in larger GWAS meta-analyses by the MIGen and CARDIoGRAM Consorta 33 and was in strong LD with the SNPs most strongly associated in FHS with CAC (rs1333045, r 2 =0.76 in FHS) and abdominal diameter (rs1333046, r 2 =0.87 in FHS). The risk alleles at 9p21.3 were weakly associated in FHS with increased ascending and descending aortic dimensions and moderately associated with increased abdominal aortic dimensions (Table 5) . A prior peak GWAS and replication SNP (rs10811661) for type 2 diabetes mellitus in multiple populations (eg, Grarup et al 4 ) was also associated in the present study population with type 2 diabetes mellitus (P<7.03×10 −4 ), which supports prior results. As noted previously, this variant was not correlated with the CVD-and subclinical CVD-associated alleles. Results in multivariable-adjusted models for all of the traits and disease end points did not differ substantially (data not shown). Overall, these findings show a consistent direction of effect of 9p21.3 SNPs with subclinical atherosclerosis, aortic dimensions, and MI, with at most weak associations with traditional CVD risk factors. Plots of region-specific associations for the phenotypes examined along with Framingham-specific LD and gene annotation are shown in the Figure. 
Leukocyte and Platelet Gene Expression Associations
There were strong and independent expression associations of SNPs with CDKN2B and short isoforms of ANRIL (EU741058, DQ485454) in leukocytes (Table 6 ), but not for CKDN2A or the long isoform of ANRIL (NR_003529). We did not observe any associations that survived multipletest correction for CDKN2A or for any of the transcripts in platelets. The pairwise transcript correlations, after adjustment for the mean of 3 housekeeping genes in samples that had each transcript assayed, with cycle threshold <30 are given in online-only Data Supplement Table VII. Regional Samples sizes separated by virgules reflect cases/controls. AAC indicates abdominal artery calcium; AAO, ascending thoracic aorta at the level of right pulmonary artery; ABAO, abdominal aorta at the aortic-common iliac bifurcation; ABAO-5, abdominal aorta 5 cm above the aortic-common iliac bifurcation; CAC, coronary artery calcium; CVD, cardiovascular disease; DAO, descending thoracic aorta at the level of right pulmonary artery; HDL, high-density lipoprotein; MI, myocardial infarction; SE, standard error; and SNP, single-nucleotide polymorphism. by guest on January 31, 2018 http://circ.ahajournals.org/ Downloaded from association plots for all 4 transcript levels in leukocytes are shown in the Figure. 
CNV at 9p21.3
We detected no common (MAF >1%) CNV gains or losses at 9p21.3 by our methodology in the following coordinate range: 20 951 906 to 23 055 716. The most common events were clustered in a region 3′ of ANRIL and 5′ of DMRTA1 (from 22 273 153-22 366 805). Among ≈8700 samples, the most common copy number gain was at rs10811687 (position 22 293 833, n=73, MAF=0.84%), and the most common copy number loss was at rs1360137 (position 22 366 805, n=16, MAF=0.18%). When copy number gains and losses were combined at each position, rs10811687 showed the greatest number of events (73 copy number gains, 11 copy number losses, combined MAF=0.97%). Plotting of single SNP copy number signals (Figure) showed that uncommon events were observed throughout the sequenced region.
Discussion
The chromosome 9p21.3 locus containing CDKN2A, CDKN2B, and ANRIL is one of the most important and consistently associated loci to emerge from modern genetic studies using GWAS to study CVD susceptibility. The locus has been the target of considerable further genetic and functional studies since the initial discovery, but the functional mechanisms contributing to disease remain unknown. To the best of our knowledge, this is the first study to report on resequencing of the region coupled with a comprehensive examination of associations with subclinical and clinical CVD and risk factors, CNV, and gene expression, all within a single community-based population of large sample size. At least 2 other studies have reported sequencing 9p21.3 in smaller samples. One study reported no improvement in resolving stronger functional variants after resequencing of 45 samples combined with imputation and fine-mapping. 22 A second study reported resequencing 9p21.3 in 50 individuals with evidence that supports risk-associated alleles having effects on expression of CDKN2B and ANRIL through modulation of enhancer binding. 18 The present study used a resequencing strategy in population extremes consisting of clinically affected individuals, those with extreme levels of subclinical coronary atherosclerosis, and healthy matched control subjects, whereas the prior studies used resequencing strategies without considering clinical phenotypes. A further strength of the present study is the follow-up in a large cohort with expression, subclinical, and clinical measures that were analyzed. Samples sizes separated by virgules reflect cases/controls. AAC indicates abdominal artery calcium; AAO, ascending thoracic aorta at the level of right pulmonary artery; ABAO, abdominal aorta at the aortic-common iliac bifurcation; ABAO-5, abdominal aorta 5 cm above the aortic-common iliac bifurcation; CAC, coronary artery calcium; CVD, cardiovascular disease; DAO, descending thoracic aorta at the level of right pulmonary artery; HDL, high-density lipoprotein; MAF, minor allele frequency; MI, myocardial infarction; SE, standard error; and SNP, single-nucleotide polymorphism.
* After the discovery sequencing stage, we found no variant discovered by sequencing with MAF >0.75% with an obvious link to protein function or splicing that was also associated with CAC or MI (Results; Table2). Likewise, in a survey of ≈8700 individuals, we did not find strong evidence for common CNV in the 9p21.3 region that could directly influence gene function, consistent with a prior report on CNV and MI. 1 We did observe a slight overrepresentation of rare variants (MAF <0.5%) in MI and high CAC individuals after sequencing compared with control subjects (onlineonly Data Supplement Table V) . Although rare events are proposed to have the potential to create synthetic common disease associations, 34 the idea remains controversial, 35 and confirmation of this hypothesis raised by the present study would require thorough characterization and replication of all rare and common events in 9p21 and their functional impacts and associations. We followed this hypothesis with independent burden testing from subanalysis of whole genome sequencing data in the ARIC and CHS studies, but the results did not implicate any gene subregions and only approached significance across the whole region in sequence kernel association test analysis, which included both common and rare variant effects. Our results for 9p21 may be consistent with the suggested pattern that the genetic variance of complex traits is mainly accounted for by many variants and loci with modest effects. [36] [37] [38] We found links between common variation at 9p21.3 and expression of some transcripts within the region. In leukocyte and platelet samples that were also densely genotyped, we found that previously reported variants for 9p21.3 clinical associations were associated with decreased transcript levels of short isoforms (EU741058, DQ485454) of the noncoding RNA ANRIL (eg, rs1333049, G allele on forward strand [MAF 49 .4%]; β, −0.15; SE, 0.05; P<4.1×10 −3 ) but not with a long isoform (NR_003529.1; β, 0.02; SE, 0.05; P<0.61). The present study represents the largest set of samples characterized for gene expression genetics at 9p21.3 to date among at least 10 other studies. 3, [14] [15] [16] [17] [18] [19] [20] [21] 39 Although there are substantial differences in tissues, probes, and isoforms targeted across these studies that may limit direct comparisons, the overall findings of the present study are consistent with several prior findings. First, there is consistency among the largest studies, including the present study, that the MI/CAC risk alleles are most strongly associated with decreased levels of short isoforms of ANRIL 14, 39 and have a weaker association 39 or no association 14 with CDKN2A/2B or a long ANRIL isoform, despite the location of the risk alleles adjacent to the 3′ end of the long isoform. Some studies were unable to distinguish between short and long isoforms because of their assay designs. [16] [17] [18] 20 Second, regardless of genotypes, we observed correlation in leukocytes and platelets of the short and long isoforms of ANRIL (r=0.784 in leukocytes) and between CDKN2A and CDKN2B (r=0.585 in leukocytes), which supports the coexpression of those genes in several tissues and is consistent with findings in other studies. 14, 16, 17, 19, 39 The correlations between ANRIL isoforms and CDKN2A/2B appear to indicate positive correlation between ANRIL isoforms and CDKN2A and negative correlation with CDKN2B after accounting for housekeeping genes (online-only Data Supplement Table VII ). The negative correlation of ANRIL expression with CDKN2B expression is consistent with experimental work indicating that ANRIL may inhibit CDKN2B expression and suggests this relationship could be a key mechanistic driver. 15, 18, 40 We discovered much stronger expression associations for the short isoforms of ANRIL (rs944799; β, 0.30; SE, 0.05; P<4.6×10 −9 ) and CDKN2B (rs598664, β, −0.36; SE, 0.07; P<6.1×10 −7 ) in leukocytes than those directly linked to the MI/CAC alleles. These variants appear relatively distinct from the MI/CAC alleles (rs944799, MAF 49.8%, r 2 to rs1333049=0.22; rs598664, MAF 11.0%, r 2 to rs1333049=0.01). The SNP rs598664, strongly associated with decreased CDKN2B expression, was modestly associated with increased CAC levels (P<1.6×10 −3 ) but was not associated with prevalent (P=0.66) or incident (P=0.58) MI, although our power to detect disease association may be limited given relatively low MAF and low numbers of clinical events. Although the SNP rs944799 showed modest association with increased CAC levels (P<0.02) and trended toward significant association with increased odds of prevalent (P=0.06) and incident (P=0.10) MI, in analyses that adjusted for rs1333049 or rs1333045, rs944799 was no longer significant for association with CAC, which suggests any associations are likely caused by a modest LD with the previously described risk variants (data not shown). Despite a high MAF, rs944799 is not present on any commercial genotyping arrays and has no moderate LD partners (r 2 >0.6) even in the 1000 genome phase 1 data, which indicates that our strategy of resequencing, follow-up genotyping, and association with gene expression and high-resolution clinical phenotypes led to the discovery of a new candidate functional expression quantitative trait locus for ANRIL that may not have been adequately ascertained in prior studies.
At a nominal significance level (P<0.05), 77 variants and 37 variants were associated with ANRIL and CDKN2B expression, respectively, in leukocytes, whereas only 7 variants were 16 which suggests there are multiple independent genetic signals for the expression of each gene. Although the prior study 16 did not distinguish between short and long isoforms of ANRIL, when we attempted to compare results, we found several consistent signals among 15 SNPs we had in common (online-only Data Supplement Table VIII ). Several different isoforms of ANRIL in blood and carotid plaque were also previously associated with risk SNPs and with extent of atherosclerosis severity, which further builds a case for the importance of ANRIL expression in a relevant tissue and sample. 39 A previous study that included samples from FHS suggested that 9p21.3 alleles may contribute to platelet reactivity. 41 Here, we found 9p21.3 gene expression genetic results in platelets were less significant than those in leukocytes. This may be attributable to the anuclear nature of platelets and lower transcript abundance. The short isoforms of ANRIL were not well expressed in platelets, whereas the long isoform (NR_003529.1) and CDKN2A and CDKN2B were well expressed, with modest associations observed with variants, decreased expression of NR_003529.1, and increased expression of CDKN2A (Table 6 ). The top associated variants in platelets were not in LD with the CAC-and MI-associated variants, which indicates their effects are not likely linked to known disease associations at this time. If 9p21.3 disease associations are mediated in part through effects on platelet reactivity, it is likely via a mechanism other than effects on platelet gene expression.
Conclusions and Implications
In a large, well-phenotyped cohort, we applied multiple genomic technologies to the study of the 9p21.3 association region, including sequencing, follow-up genotyping, CNV, gene expression, and associations with high-resolution measures of clinical and subclinical CVD and risk factors. We report associations that are consistent with findings from prior studies of MI and other forms of CVD, aortic aneurysm, CAC, and type 2 diabetes mellitus, confirming the impact of 9p21.3 CVD associations in a single population. Consistent with prior studies, we found little evidence that 9p21.3 associations were mediated via CNV 1 or through traditional risk factors. After comprehensive sequencing, we failed to find any common or uncommon variants with clear functional effects that were linked to protein-coding genes (eg, splicing or protein defects). By contrast, we found multiple strong transcript-SNP associations, with both common and uncommon variants, which suggests complex genetic regulation of the transcripts in the region. The strongest disease-associated variants were only modestly associated with decreased expression of ANRIL, and ANRIL expression was inversely correlated with CDKN2B in the present sample, consistent with several other large studies. If disease progression is altered through modulation of ANRIL or CDKN2B transcript levels, this raises the question of why those variants most strongly associated with transcript levels in leukocytes are not strongly associated with disease. One potential explanation is that the modulation of transcript levels that leads to higher risk is specific to particular conditions of regulatory activation or specific tissues that are not easily detected in cross-sectional tissue surveys. A recent effort to characterize the regulatory relationships in the region supports the idea that there is a complex regulatory space and that disease-associated alleles may have condition-and tissue-specific effects. 18 Further detailed studies in multiple tissues are necessary to understand functional mechanisms and the key regulatory interactions, along with genetic follow-up in large clinical cohorts to determine how these variants influence disease and which ones are most important for potential clinical applications.
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CLINICAL PERSPECTIVE
The chromosome region 9p21.3 of the human genome is among the strongest and most consistently nonmendelian gene regions associated with subclinical coronary artery disease, coronary artery disease, and myocardial infarction, but questions remain about the impacted genes and mechanisms. We tested the hypothesis that rare variants, deletions, or duplications in the region may underlie the associations in the region and directly alter expression of both protein-coding and noncoding genes. The present study sequenced the 9p21.3 region of the genome in myocardial infarction case subjects (n=94), individuals with no myocardial infarction but a high burden of subclinical disease (n=94), and control individuals (n=93). Identified genetic markers were tested in thousands of participants in the Framingham Heart Study in association with disease risk factors, subclinical vascular disease, clinical myocardial infarction, and RNA levels of genes in the region. Additional sequencing data from myocardial infarction case and control subjects in other studies were used to examine associations of rare variants with disease. We observed that modest effects of frequent population variants (single-nucleotide polymorphisms) that alter RNA levels produced from the CDKN2B gene and/or the non-protein-coding gene ANRIL are the most likely explanation for subclinical and clinical disease associations at 9p21.3. These findings suggest pathways for therapies to prevent or treat subclinical and clinical coronary artery disease and suggest that further mechanistic studies may require detailed tissue-and context-dependent molecular studies. A lack of association of 9p21.3 markers with traditional cardiovascular risk factors argues strongly against mechanisms that involve these known risk factors. is an integrative pipeline which can achieve high quality for (1) variant site discovery, (2) genotype likelihood estimation, and (3) genotype/haplotype inference via imputation.
SUPPLEMENTAL MATERIAL
The SNPTools algorithm includes a variance ratio statistic for the initial site discoveries.
This statistic compares the difference in variation contributed from the variant read coverage (in case that they are true positives), and the variation that would be due to sequencing and mapping errors (in case that they are false positives). The larger the variance ratio statistic, the more likely the site is a true polymorphic site. In the current dataset, we applied the default cutoff of 1.5. SNPTools next estimates the genotype likelihoods (GLs) by clustering all candidate sites within each particular BAM to overcome data heterogeneity using a mixture model. This step is named the "BAM- All nominally significant (p<0.05) expression associations in either study are highlighted in grey All nominally significant (p<0.05) clinical associations in the current study are highlighted in blue n.s. = not significant (beta and se are only given for nominally significant results)
